7月3日,艾伯维今日宣布,维奈克拉片(商品名:唯可来)已获 NMPA 批准,用于治疗既往至少接受过一种治疗的伴17p 缺失的成人慢性淋巴细胞白血病或小淋巴细胞淋巴瘤患者(CLL/SLL)。此前 2020 年,该产品已在中国获批用于与阿扎胞苷联合用于治疗因合并症不适合接受强诱导化疗,或者年龄 75 岁及以上的新诊断的成人急性髓系白血病(AML)患者。来源:艾伯维官微维奈克拉是全球首个获批用于 CLL...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.